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A sample was submitted for serologic evaluation from a pregnant
patient with immune thrombocytopenic purpura (ITP) for possible
transfusion in the future because of a decreased platelet count.
Anti-D and -E were identified in the patient’s serum using several
antibody identification techniques, and anti-D was recovered in an
acid eluate prepared from the patient’s red cells.  It was discovered
that WinRho™ had been administered to treat the ITP.  This prod-
uct has been licensed for treatment of nonsplenectomized D+ chil-
dren and adults with ITP to increase the platelet count.
Administration of anti-D to D+ individuals for treatment of ITP can
cause a red cell anemia.  Immunohematology 1999;15:69–70.
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The administration of Rh Immune globulin (RhIG) as
antenatal prophylaxis has become accepted practice;
therefore, it is not uncommon to detect anti-D in the
serum of D– pregnant women during the third
trimester and at delivery.
Since June 1995, Rho (D) Immune Globulin
Intravenous (Human), known as WinRho SDF™ (NABI,
Boca Raton,FL),has been licensed by the U.S. Food and
Drug Administration for treatment of D+ children with
chronic or acute immune thrombocytopenic purpura
(ITP), D+ adults with chronic ITP, and children and
adults with ITP secondary to HIV infection, to increase
platelet counts.1 Anti-D, -C, -E, -G, -V, and -Fya have been
detected in the serum of D+ individuals after infusion
of RhIG and also have been recovered in eluates pre-
pared from their red blood cells (RBCs).2
A sample was submitted to our laboratory for sero-
logic evaluation on a pregnant woman with a diagnosis
of ITP. The workup was requested because it was
thought that the patient may require future transfusion
therapy. The list of medications included RhIG,
Carafate, Solumedrol, Solucort, and Benadryl. The RhIG
was identified as WinRho SDF™ and was used for the
treatment of ITP.
Case Report
Blood samples from a 16-year-old female were sub-
mitted to the reference laboratory for antibody identi-
fication. Her diagnosis was pregnancy and ITP. The
request form indicated this to be the first pregnancy
with a due date in approximately 8 weeks. There was
no transfusion history recorded, and the assumption
was the patient had not been transfused previously.
The patient was receiving RhIG, Solumedrol, Solucort,
and Benadryl during her pregnancy.
Materials and Methods
Routine tests were performed with standard meth-
ods and licensed commercial reagents. ABO and Rh
were determined with monoclonal anti-A, monoclonal
anti-B (Gamma Biologicals, Houston, TX) and blended
monoclonal-polyclonal anti-D antisera (Ortho-Clinical
Diagnostics, Raritan, NJ). The Rh phenotype was deter-
mined using monoclonal anti-C, -E, -c, and -e (Ortho-
Clinical Diagnostics). Initial antibody identification
was performed using MTS ID-Micro Typing System™
(Ortho-Clinical Diagnostics). Standard tube test meth-
ods were performed using an in-house panel of reagent
RBCs with known phenotypes (Blood Systems
Laboratories, Scottsdale, AZ), a low-ionic-strength solu-
tion (LISS) technique (N-Hance, Gamma Biologicals),
polyethylene glycol (PEG; Blood Systems Laboratories),
and monospecific anti-IgG (Immucor, Inc., Norcross,
GA). Direct antiglobulin testing (DAT) was performed
using polyspecific antihuman globulin (AHG) contain-
ing anti-IgG and -C3d, monospecific anti-IgG, monospe-
cific anti-C3b, -C3d (Immucor) and a 6% albumin con-
trol (Blood Systems Laboratories). An acid eluate
prepared from the patient’s IgG-coated RBCs (Elu-Kit
II, Gamma Biologicals) was tested with a panel of
reagent RBCs using the routine method listed in the
reagent circular.
An autologous adsorption was performed to deter-
mine if the antibody detected was an allo- or an autoan-
tibody. The patient’s RBCs were treated with 0.2 M
dithiothreitol and 1% ficin in pH 7.3 phosphate-
buffered saline, incubated for 30 minutes at 36°C to
38°C, and washed to remove any residual reagent. One
volume of serum was incubated for 30 minutes at 36°C
to 38°C with two volumes of treated RBCs. The
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adsorbed serum was harvested and tested with a LISS
technique using an in-house panel of reagent RBCs.
Results
The patient’s RBCs typed as group A, D+C+E–c–e+.
The initial antibody identification performed using the
MTS ID-Micro Typing System™ appeared to be anti-D
with weak reactions with two of three E+ cells. A sub-
sequent panel performed using a LISS technique
appeared to be anti-D. Antibody identification using PEG
appeared to be anti-D and a weakly reactive anti-E. The
DAT was strongly positive with polyspecific AHG and
anti-IgG, and negative with anti-C3b, -C3d, and the 6%
albumin control. An acid eluate prepared from the
patient’s RBCs reacted with the D+ cells and was nonre-
active with D– cells. The autoadsorbed serum was non-
reactive with D+ reagent RBCs.
Discussion
A possible interpretation of the initial serologic find-
ings was an autoimmune process with relative anti-D
specificity. With the diagnosis of ITP, an autoimmune
disorder, a warm-reactive autoagglutinin could be pos-
sible. A discussion with the submitting facility dis-
closed that the patient had received WinRho SDF™ to
treat ITP. (Because the patient is D+, she would not be
a candidate for antenatal RhIG prophylaxis.)  According
to the reagent circular,administration of WinRho SDF™
to nonsplenectomized D+ individuals has been shown
to increase platelets in ITP patients usually within 1 to
2 days and peak within 7 to 14 days after initiation of
therapy.1 Although the duration of the response is vari-
able, the average duration is approximately 30 days. A
decrease in hemoglobin can be expected with this
treatment.1
The rationale behind administration of intravenous
anti-D is the blockade of Fc receptors of the mononu-
clear phagocytes located in the spleen by antibody-coat-
ed RBCs. It is also felt that the spleen is the site of
antiplatelet antibody production. Splenectomy as a treat-
ment for ITP would remove the site of platelet destruc-
tion and platelet antibody production. The decision to
treat a patient with WinRho SDF™ or perform a splenec-
tomy depends on the physician’s evaluation of the dis-
ease state.
Often the diagnosis listed on a reference laboratory
request form or in a hospital computer system is not the
patient’s primary disease. When anti-D is identified in a
D+ patient, further inquiry is necessary to determine the
patient’s actual disease diagnosis, and if ITP is the diag-
nosis, it is necessary to determine if WinRho SDF™ has
been administered as a treatment for ITP. Since this lab-
oratory’s encounter with this patient, we have identified
anti-D in another D+ patient with ITP and consulted
with other facilities that encountered these same sero-
logic findings in two patients in less than 6 months. This
situation will become more common as this form of
treatment for ITP increases because of its efficacy, lower
cost compared to intravenous immune globulin, and rel-
atively few side effects (unpublished data, 1998,
AABB/ARC Reference Laboratory Meeting, Peachtree,
GA). The mean hemoglobin decrease 7 days after trans-
fusion is 0.8 g/dL; therefore, transfusion has not been
required because of this therapy.3 Should a patient need
a transfusion, the recommendation is to transfuse D–
units when the patient needs oxygen-carrying capacity
and D+ units when oxygen-carrying capacity is ade-
quate.4 This strategy will maintain the Fc blockade,
which allows the platelet count to increase.
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